ACST - Acasti gets patents related to brain hemorrhage drug GTX-104 pain therapy GTX-101

Acasti Pharma (NASDAQ:ACST) said it received three composition of matter patents for brain hemorrhage therapy GTX-104 from the U.S. Patent and Trademark Office, the Japanese Patent Office, and the Australian Patent Office. In addition, one new patent for GTX-104 was awarded by the Indian Patent Office, the company said in a June 14 press release. These patents are all valid until 2037. Acasti said GTX-104 is a novel formulation of nimodipine for IV infusion to treat patients with Subarachnoid Hemorrhage (SAH), which is caused by a ruptured aneurysm. SAH is a bleeding in the space between the brain and the surrounding membrane (subarachnoid space). Acasti added that it is working with the U.S. FDA to start a phase 3 trial of GTX-104. In addition, the company said that Canadian Intellectual Property Office has issued a notice of allowance for a composition of matter patent for GTX-101, a topical spray of bupivacaine

For further details see:

Acasti gets patents related to brain hemorrhage drug GTX-104, pain therapy GTX-101